EDSA > super low float > 8.25 > "Health Canada's expedited review process and subsequent approval of our Clinical Trial Application represents a significant step in developing new drugs that can treat the underlying conditions induced by the SARS-CoV-2 infection," said Dr. Par Nijhawan, Chief Executive Officer of Edesa. "We greatly appreciate the actions being taken by the government to expedite COVID-19 applications and provide support for clinical studies."
News 
Market Data 
Discover 
